Protein kinase inhibitors: contributions from structure to clinical compounds

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

(2008) Allan Wissner et al.   ARCHIV DER PHARMAZIE

Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on

(2008) Wolfram E. Samlowski et al.   BJU INTERNATIONAL

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality

(2008) G Milano et al.   BRITISH JOURNAL OF CANCER

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

(2008) B. Shor et al.   CANCER RESEARCH

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

(2008) B. I. Rini   CLINICAL CANCER RESEARCH

Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway

(2008) J. S. Sebolt-Leopold   CLINICAL CANCER RESEARCH

Doing more than just the structure—structural genomics in kinase drug discovery

(2008) Brian D Marsden et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation

(2008) Sonja Baumli et al.   EMBO JOURNAL

Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib

(2008) Navratna Vajpai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

(2008) Amit Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel 2,3-Dihydro-1,4-Benzoxazines as Potent and Orally Bioavailable Inhibitors of Tumor-Driven Angiogenesis∥

(2008) Daniel S. La et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification ofN-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†

(2008) Paul G. Wyatt et al.   JOURNAL OF MEDICINAL CHEMISTRY

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

(2008) Oliver Hantschel et al.   LEUKEMIA & LYMPHOMA

The ground state of embryonic stem cell self-renewal

(2008) Qi-Long Ying et al.   NATURE

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

(2008) K Bettayeb et al.   ONCOGENE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drugging the Plasmodium kinome: the benefits of academia–industry synergy

(2008) Didier Leroy et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

(2007) Lecia V. Sequist et al.   Annual Review of Medicine

Targeting phosphoinositide 3-kinase—Moving towards therapy

(2007) Romina Marone et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

CDK inhibitors in cancer therapy: what is next?

(2007) Marcos Malumbres et al.   TRENDS IN PHARMACOLOGICAL SCIENCES